Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Other financing activities (2020 - 2026)

Treace Medical Concepts posted quarterly Other financing activities of $6000.0 for Q1 2026, down 25.0% on a QoQ basis from $8000.0 in Q1 2020.

Treace Medical Concepts (TMCI) has 2 years of Other financing activities data on file, last reported at $6000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Other financing activities changed N/A year-over-year to $6000.0; the trailing twelve-month figure through Mar 2026 stood at $6000.0 (changed N/A YoY), and the FY2025 full-year result was $1.2 million, changed N/A from the prior year.
  • Other financing activities for Q1 2026 stood at $6000.0, down from $8000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $6000.0 in Q1 2026 and bottomed at $6000.0 in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Treace Medical Concepts 234.79 Mn 182.94 Mn 37.41 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 6,000.00
Mar 31, 2026 6,000.00
Mar 31, 2020 8,000.00
Mar 31, 2020 8,000.00